E

Erasmus MC Biomedical Fund

10 employees

Erasmus MC Biomedical Fund finances early-stage companies in the biotechnology and biomedical field and is an independent investment firm.

Investor insights

Sectors invested in

Rare Diseases3
Immunotherapy3
Biotechnology3
Acute Myeloid Leukemia3
Pemphigus Vulgaris3
Immune Thrombocytopenia3
chronic inflammatory demyelinating polyneuropathy3
Myasthenia Gravis3
high-risk myelodysplastic syndromes3
Immunology3
Clinical Trials3
Oncology3
Antibody based medicines3
Therapeutics3
Autoimmune diseases3
Medical2
Health Care2
Life Science1

Funding rounds participated in

$14M sweet spot round size

Most of their 6 investments are in rounds between $4.5M and $14M

Investor type

Venture Capital

Basic info

Industry

venture capital and private equity principals

Date founded

2007

Investments made

a

argenx raised $44M on December 1, 2011

Investors: LSP (Life Sciences Partners), Omnes, OrbiMed Advisors, Seventure Partners, Forbion and Erasmus MC Biomedical Fund

a

argenx raised $4.5M on February 11, 2010

Investors: BGV (BioGeneration Ventures), Thuja Capital, Omnes, EQT Life Sciences, Forbion and Erasmus MC Biomedical Fund

a

argenx raised $14M on September 10, 2009

Investors: BGV (BioGeneration Ventures), Forbion and Erasmus MC Biomedical Fund

C

Cavadis raised undisclosed on May 26, 2009

Investors: Utrecht Holdings (Universiteit Utrecht), Thuja Capital and Erasmus MC Biomedical Fund

U

Undisclosed raised undisclosed on April 1, 2008

Investors: Erasmus MC Biomedical Fund

R

RiverD International raised undisclosed on December 20, 2007

Investors: TIIN Capital B.V. and Erasmus MC Biomedical Fund

FAQ